OPKO Health takes over Farmadiet
The acquisition allows OPKO to establish presence in the European Union and allows near term product commercialization synergies through the introduction of Farmadiet’s products to OPKO’s existing Latin
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.